Loading
A phase 2 trial of SSGJ-706, Carboplatin and Pemetrexed in non-small-cell lung cancer, run by Shenyang Sunshine Pharmaceutical Co., LTD., now recruiting.
A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients is a phase 2 interventional study registered as NCT07171606 by Shenyang Sunshine Pharmaceutical Co., LTD., with 240 participants planned, started 2025-10-24 and due to reach its primary completion in 2026-08-31. Interventions recorded: SSGJ-706, pemetrexed /carboplatin, Carboplatin/Paclitaxel and PD-1 Inhibitor + Chemotherapy.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares 3SBio and the tag pipeline.
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
Shares 3SBio and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/